The committee's recommendation was based on data from the TROPION-Breast01 trial, which also supported the US approval of Datroway in January.
The firms will evaluate two adjuvant treatment options, Datroway with rilvegostomig or rilvegostomig monotherapy, against standard-of-care treatment.
The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...
AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast ...
GlobalData on MSN19h
Tubulis doses first subject in Phase I/IIa solid tumour therapy trialTubulis has dosed the first subject in the multicentre Phase I/IIa 5-STAR 1-01 trial to clinically evaluate its second drug ...
Immunome's varegacestat is in a phase 3 trial in patients with desmoid tumors that should produce results in H2'25. Read why ...
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...
OQY-3258, also known as ESG401, is an anti-TROP2 ADC currently under evaluation in three clinical trials: A Phase 1a/1b clinical trial for patients with solid tumors (NCT04892342). A Phase 3 study in ...
The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, ...
Scientists from the National Institutes for Food and Drug Control have characterized antibody-drug conjugates (ADCs) using ...
Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback